Home/Hedge Fund Intelligence/Arcus Biosciences, Inc.
NYSE: RCUSStockForm 13F30 Jun 2026

Hedge funds that hold Arcus Biosciences, Inc. NYSE: RCUS

CUSIP 03969F109 · who reports it, how much, and how much it matters to them

28 of the 720 hedge fund managers we track reported shares of Arcus Biosciences, Inc. (NYSE: RCUS) on Form 13F for 30 June 2026. Between them they reported USD 501m. The largest position belongs to Suvretta Capital Management, at USD 147m.

Managers reporting it28of 720 we track
Value they reportUSD 501mshares only, 30 Jun 2026
Funds they run344with a file on PPLI.com
Largest positionUSD 147mSuvretta Capital Management
Typical weight0.1%median share of a manager's book
Heaviest weight2.7%Suvretta Capital Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

28 managers, USD 501m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Arcus Biosciences, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Suvretta Capital Management4 funds on PPLI.comUSD 147m2.7%
2Citadel Advisors32 funds on PPLI.comUSD 97m0.0%
3Marshall Wace LLP84 funds on PPLI.comUSD 60m0.0%
4Samlyn Capital8 funds on PPLI.comUSD 48m0.8%
5Sofinnova Investments1 fund on PPLI.comUSD 29m1.5%
6Baker Bros. Advisors2 funds on PPLI.comUSD 26m0.1%
7Logos Global Management1 fund on PPLI.comUSD 20m0.9%
8Two Sigma Investments35 funds on PPLI.comUSD 20m0.0%
9Dafna Capital Management6 funds on PPLI.comUSD 14m2.6%
10Rock Springs Capital Management2 funds on PPLI.comUSD 5.5m0.3%
11Boothbay Fund Management2 funds on PPLI.comUSD 4.8m0.1%
12PFM Health Sciences3 funds on PPLI.comUSD 4.7m0.4%
13Hudson Bay Capital Management8 funds on PPLI.comUSD 4.3m0.0%
14Platinum Investment Management11 funds on PPLI.comUSD 4.1m1.0%
15Millennium Management6 funds on PPLI.comUSD 4.1m0.0%
16Schonfeld Strategic Advisors30 funds on PPLI.comUSD 3.8m0.0%
17D. E. Shaw & Co.15 funds on PPLI.comUSD 3m0.0%
18Persistent Asset Partners10 funds on PPLI.comUSD 1.8m0.5%
19Burkehill Global Management5 funds on PPLI.comUSD 1.5m0.1%
20Balyasny Asset Management25 funds on PPLI.comUSD 704,0000.0%
21Squarepoint Ops7 funds on PPLI.comUSD 467,0000.0%
22Entrypoint Capital1 fund on PPLI.comUSD 408,0000.1%
23Bayforest Capital1 fund on PPLI.comUSD 392,0000.4%
24Capstone Investment Advisors25 funds on PPLI.comUSD 310,0000.0%
25Verition Fund Management3 funds on PPLI.comUSD 308,0000.0%
26Campbell & Company Investment Adviser8 funds on PPLI.comUSD 290,0000.0%
27Seelaus Asset Management8 funds on PPLI.comUSD 202,0000.1%
28The Quarry1 fund on PPLI.comUSD 9250.0%
Next: where it matters most
Where it matters most

For Suvretta Capital Management it is 2.7% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Suvretta Capital ManagementUSD 147m2.7%
2Dafna Capital ManagementUSD 14m2.6%
3Sofinnova InvestmentsUSD 29m1.5%
4Platinum Investment ManagementUSD 4.1m1.0%
5Logos Global ManagementUSD 20m0.9%
6Samlyn CapitalUSD 48m0.8%
7Persistent Asset PartnersUSD 1.8m0.5%
8PFM Health SciencesUSD 4.7m0.4%
9Bayforest CapitalUSD 392,0000.4%
10Rock Springs Capital ManagementUSD 5.5m0.3%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Arcus Biosciences, Inc.

What is the ticker symbol of Arcus Biosciences, Inc.?

Arcus Biosciences, Inc. trades under the symbol RCUS on the New York Stock Exchange. Its CUSIP, the code used on Form 13F, is 03969F109.

Which hedge funds own Arcus Biosciences, Inc. (NYSE: RCUS)?

28 of the 720 hedge fund managers PPLI.com tracks reported Arcus Biosciences, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 147m), Citadel Advisors (USD 97m), Marshall Wace LLP (USD 60m), Samlyn Capital (USD 48m) and Sofinnova Investments (USD 29m).

How many hedge funds hold Arcus Biosciences, Inc.?

28 managers in our coverage reported it, and between them they run 344 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Arcus Biosciences, Inc.?

Suvretta Capital Management, where the position was 2.7% of the reported 13F book at 30 June 2026.

Does this show who is short Arcus Biosciences, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Arcus Biosciences, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.